Results 41 to 50 of about 18,139 (185)

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

The frequency of agitation due to inappropriate use of naltrexone in addicts

Advanced Biomedical Research, 2014
Background: There is a high tendency among specialists to treat the addicts with naltrexone; withdrawal symptoms are frequent after taking naltrexone along with opioids.
Sima Siadat, Nastaran Eizadi-Mood, Ali Mohammad Sabzghabaee, Farzad Gheshlaghi, Ahmad Yaraghi   +4 more
doaj   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Addiction‐related problems in Japan: A regional perspective

Addiction, EarlyView.
Abstract Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.
Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino, Hidehiko Takahashi, Kenji Takeuchi, Atsumi Nitta, Takeshi Honjo, Hiroshi Matsumoto, Tsuyoshi Miyakawa, Toshiya Murai, Toshihiko Matsumoto, Kazuyuki Nakagome, Kazutaka Ikeda   +19 more
wiley   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta-Analysis. [PDF]

Eur Eat Disord Rev
ABSTRACT Objective To compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta‐analysis. Method We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications
Hodrob T, Ismail I, Abusalameh A, Andonie CR, Ayesh O, Ayesh H.   +5 more
europepmc   +2 more sources

Brief report: Ketamine‐assisted “bridge therapy” for opioid tapering in complex cases

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25‐year‐old woman with OUD, chronic pain, and major depressive disorder underwent an 8‐week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Results Methadone
Mariana C. de Oliveira, Cláudia C. de Araujo Palmeira, André B. Negrão, Ziyad A. Hadi, Julia R. Arana, Rita de Cássia Ferreira Duarte, Joice L. P. da Silva, Gustavo K. Matsui, João F. D. Rapozero, Douglas H. Crispim, André Malbergier, João M. Castaldelli‐Maia   +11 more
wiley   +1 more source

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

Substance Abuse and Rehabilitation, 2011
Paolo Mannelli, Kathleen S Peindl, Li-Tzy WuDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USAPurpose: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that ...
Peindl K, Mannelli P, Wu LT
doaj  

Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

BMC Research Notes, 2012
Background Naltrexone has been proven to be an effective treatment option for the treatment of alcohol dependency. In this article we introduce a reliable and simple method developed for the simultaneous determination of naltrexone and 6-β-naltrexol in ...
Heinälä Pekka, Lahti Tuuli, Sinclair David, Ariniemi Kari, Lillsunde Pirjo, Alho Hannu   +5 more
doaj   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source